Truist Financial’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Truist Financial’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.99M	Sell	52,126 -4,962	-9%	-$173K	﹤0.01%	1384
2026 Q1	$1.96M	Buy	+57,088	New	+$1.95M	﹤0.01%	1337
2023 Q2	–	Sell	-45,988	Closed	-$1.2M	–	2598
2023 Q1	$1.2M	Sell	45,988 -182,383	-80%	-$4.89M	﹤0.01%	1467
2022 Q4	$6.26M	Buy	228,371 +8,297	+4%	+$221K	0.01%	742
2022 Q3	$5.29M	Buy	220,074 +165,207	+301%	+$4.27M	0.01%	762
2022 Q2	$1.45M	Buy	54,867 +34,737	+173%	+$918K	﹤0.01%	1378
2022 Q1	$536K	Buy	+20,130	New	+$520K	﹤0.01%	1970

Other funds holding FTXH

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

MIM

Marshall Investment Management Littleton, Colorado $241M AUM 30.53% 1-Year Est. Return

AIP

Ameritas Investment Partners Lincoln, Nebraska $3.75B AUM 46.53% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Nilsine Partners Greenwood Village, Colorado $1.45B AUM 47.06% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Truist Financial's FTXH Position: Q2 2026 in Review

Truist Financial reduced its First Trust Nasdaq Pharmaceuticals ETF (FTXH) stake by 8.7% in Q2 2026, selling an estimated $173K and leaving 52,126 shares worth $1.99M. The position accounts for ﹤0.01% of the portfolio, ranked #1384.

Truist Financial first reported a position in FTXH in Q1 2022 and has held it in 7 quarters since. The position peaked at $6.26M in Q4 2022. 30 funds tracked by Wall St. Rank hold FTXH as of Q2 2026.

Truist Financial held 52,126 shares of First Trust Nasdaq Pharmaceuticals ETF worth $1.99M as of Q2 2026.
Truist Financial sold 4,962 First Trust Nasdaq Pharmaceuticals ETF shares in Q2 2026, an estimated $173K.
First Trust Nasdaq Pharmaceuticals ETF made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #1384 holding.
Truist Financial first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q1 2022 and has held it in 7 quarters since.
Truist Financial's First Trust Nasdaq Pharmaceuticals ETF position peaked at $6.26M in Q4 2022.
30 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.